Latest Gamma secretase Stories

MetLife Foundation today announced the recipients of its 2013 Awards for Medical Research in Alzheimer’s Disease: Yueming Li, Ph.D., member and professor, Sloan-Kettering Institute and director and professor, Graduate Program in Pharmacology, Weill Medical College of Cornell University, and Lennart Mucke, M.D., director, Gladstone Institute of Neurological Disease, Joseph B. Martin Distinguished Professor of Neuroscience and professor of Neurology, University of California, San...

NEW YORK, Dec. 4, 2012 /PRNewswire-USNewswire/ -- The Fisher Center for Alzheimer's Research Foundation (ALZinfo.org) today announced it has received the highest 4-star rating for the second consecutive year from Charity Navigator's, the nation's premier charity evaluator. Only 17% of the charities rated by Charity Navigator have received 2 or more consecutive 4-star evaluations, indicating that Fisher Center for Alzheimer's Research Foundation outperforms most other charities in...

CAMBRIDGE, Mass., July 18, 2012 /PRNewswire/ -- Satori Pharmaceuticals, a company dedicated to developing life-changing therapeutics for Alzheimer's disease (AD), announced today that its lead compound, a gamma-secretase modulator (GSM), is efficacious in preclinical models following single or multi-day dosing. This oral presentation, as well as two poster presentations related to the characteristics of Satori's GSMs, was presented at the Alzheimer's Association International...

Connie K. Ho for redOrbit.com - Your Universe Online 5 million. That’s the number of people in the U.S. suffering from Alzheimer’s disease, according to a recent CNN article. Scientists recently announced that they had discovered a gene that fights Alzheimer’s. This is a positive step forward as the gene could help develop treatments to fight the disorder. In the journal Nature, researchers explained how the gene that caused an early form of Alzheimer’s could also be created to...

CAMBRIDGE, Mass., Feb. 23, 2012 /PRNewswire/ -- Satori(TM) Pharmaceuticals, a developer of life changing therapeutics for Alzheimer's disease (AD), today announced that it has raised an additional $15 million in financing. Current investors InterWest Partners, New Enterprise Associates Inc. (NEA) and Prospect Venture Partners co-led the round. Prior to this round, Satori had raised a total of $25 million in financing which has allowed the Company to select a group of lead compounds...

NEW YORK, Aug. 11, 2011 /PRNewswire/ -- Citeline, an Informa business unit, and the world's leading research authority on pharmaceutical clinical trials recently reviewed the findings from the 14th International Conference on Alzheimer's Disease (ICAD 2011/AAIC 2011) July 16-21, 2011, noting that while pharma continues to develop beta amyloid targeting drugs, amyloid targets are moving ahead in terms of biomarkers and early warning for risk of Alzheimer's. According to Dr. Revati Tatake,...

CAMBRIDGE, Mass., July 18, 2011 /PRNewswire/ -- Satori(TM) Pharmaceuticals today announced the presentation of two posters at the Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) taking place in Paris, France, July 16-21, 2011. Both posters illuminate the unique biological activity associated with Satori's approach to the treatment of Alzheimer's disease. The posters were titled, "Gamma-secretase modulators do not show a potency shift in high expressing model...

(Ivanhoe Newswire) "“ Researchers pinpoint a small RNA that triggers cells to manufacture a particular splice variant of a key neuronal protein, potentially promoting Alzheimer's disease (AD) or other types of neurodegeneration.Like a movie with an alternate ending, a protein can come in more than one version. Although scientists have identified numerous proteins and RNAs that influence alternative splicing, they haven't deciphered how cells fine-tune the process to produce specific protein...

A drug used to treat asthma has been shown to help reduce the formation of amyloid beta, a peptide in the brain that is implicated in the development of Alzheimer's disease, according to researchers at Temple University's School of Medicine.The researchers published their findings, "Pharmacologic Blockade of 5-Lipoxygenase Improves the Amyloidotic Phenotype of an AD Transgenic Mouse Model," in the American Journal of Pathology.In previous studies, the Temple researchers discovered...

Asthma inhibitors could help control or treat the diseaseA protein known to exist in the brain for more than 30 years, called 5-lipoxygenase, has been found to play a regulatory role in the formation of the amyloid beta in the brain, the major component of plaques implicated in the development of Alzheimer's disease, according to researchers at Temple University's School of Medicine.The researchers also found that inhibitors of this protein currently used to control asthma could possibly be...